KLS Keeping Law Simple Legislation in plain English

Straight-ahead summaries built from the official bill text. We keep the source links front and center and leave the decision up to you.

Back to Connecticut

SB00191 • 2026

AN ACT CONCERNING THE PSYCHEDELIC-ASSISTED THERAPY PILOT PROGRAM.

AN ACT CONCERNING THE PSYCHEDELIC-ASSISTED THERAPY PILOT PROGRAM.

Education Healthcare
Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Public Health Committee
Last action
2026-05-26
Official status
Transmitted by Secretary of the State to Governor
Effective date
Not listed

Plain English Breakdown

The official source does not specify that the Department of Mental Health and Addiction Services runs the program, only establishes it within available appropriations.

Expanding Access to Psychedelic-Assisted Therapy

This act expands the psychedelic-assisted therapy pilot program in Connecticut.

What This Bill Does

  • Defines key terms like 'MDMA' and 'psilocybin'.
  • Establishes a pilot program for MDMA-assisted or psilocybin-assisted therapy at a medical school, funded by available state money.
  • Limits participation to qualified patients who meet specific criteria.

Who It Names or Affects

  • People with mental health conditions who qualify for the pilot program.
  • Medical schools in Connecticut that will administer the therapy.

Terms To Know

MDMA
A synthetic psychoactive drug, commonly known as ecstasy or molly, that acts as a serotonin receptor agonist and reuptake inhibitor of serotonin and dopamine.
Psilocybin
A naturally occurring substance in some mushroom species that acts as a serotonin receptor agonist.

Limits and Unknowns

  • The act does not specify when the program will end.
  • It is unclear how many people will be able to participate in the pilot program.

Bill History

  1. 2026-05-26 Connecticut General Assembly

    Transmitted to the Secretary of State

  2. 2026-05-26 Connecticut General Assembly

    Transmitted by Secretary of the State to Governor

  3. 2026-05-19 LCO

    Public Act 26-108

  4. 2026-05-06 Connecticut General Assembly

    House Passed

  5. 2026-05-06 Connecticut General Assembly

    In Concurrence

  6. 2026-04-09 Connecticut General Assembly

    Favorable Report, Tabled for the Calendar, House

  7. 2026-04-09 Connecticut General Assembly

    House Calendar Number 378

  8. 2026-04-08 Connecticut General Assembly

    Senate Passed

  9. 2026-03-16 LCO

    Reported Out of Legislative Commissioners' Office

  10. 2026-03-16 Connecticut General Assembly

    Favorable Report, Tabled for the Calendar, Senate

  11. 2026-03-16 Connecticut General Assembly

    Senate Calendar Number 49

  12. 2026-03-16 LCO

    File Number 28

  13. 2026-03-09 LCO

    Referred to Office of Legislative Research and Office of Fiscal Analysis 03/16/26 12:00 PM

  14. 2026-03-03 LCO

    Filed with Legislative Commissioners' Office

  15. 2026-03-02 PH

    Joint Favorable

  16. 2026-02-13 Connecticut General Assembly

    Public Hearing 02/18

  17. 2026-02-11 Connecticut General Assembly

    Referred to Joint Committee on Public Health

Official Summary Text

To expand access to and extend the psychedelic-assisted therapy pilot program.

Current Bill Text

Read the full stored bill text 
Senate Bill No. 191

Public Act No. 26-108

AN ACT CONCERNING THE PSYCHEDELIC -ASSISTED THERAPY
PILOT PROGRAM.
Be it enacted by the Senate and House of Representatives in General
Assembly convened:

Section 1. Section 17a-484g of the general statutes is repealed and the
following is substituted in lieu thereof (Effective July 1, 2026):
(a) As used in this section:
(1) "MDMA" means the synthetic psychoactive drug, 3,4 -
methylenedioxymethamphetamine, commonly known as ecstasy or
molly, that acts as a serotonin receptor agonist and reuptake inhibitor of
serotonin and dopamine.
(2) "Psilocybin" means a serotonin receptor agonist that occurs
naturally in some mushroom species.
(3) "Qualified patient" means an individual who is eighteen years of
age or older and meets clinical eligibility criteria established by the
institutional review board of the medical school selected to administer
the pilot program under subsection (b) of this section, including, but not
limited to, a resident of the state who is (A) a veteran, (B) a retired first
responder, or (C) a direct care health care worker.
Senate Bill No. 191

Public Act No. 26-108 2 of 2

(b) [Not later than January 1, 2023, the ] The Department of Mental
Health and Addiction Services shall establish, within available
appropriations, a psychedelic -assisted therapy pilot program, to be
administered by a medical school in the state. Such pilot program shall
provide qualified patients wit h MDMA-assisted or psilocybin -assisted
therapy as part of a research program approved by the federal Food and
Drug Administration pursuant to 21 CFR 312, as amended from time to
time. [The department shall cease to operate the pilot program when
MDMA and p silocybin have been approved to have a medical use by
the Drug Enforcement Administration, or any successor agency.]